Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal JSFK (Jurnal Sains Farmasi & Klinis) Indonesian Journal of Pharmacology and Therapy
Parwatininghati, Ni Putu
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Efek Samping Obat Gefitinib pada Pasien Kanker Paru dengan Epidermal Growth Factor Receptor (EGFR) Mutasi Positif Parwatininghati, Ni Putu; Rahmawati, Fita; Sajinadiyasa, I Gede Ketut
JSFK (Jurnal Sains Farmasi & Klinis) Vol 10 No 2 (2023): J Sains Farm Klin 10(2), Agustus 2023
Publisher : Fakultas Farmasi Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jsfk.10.2.238-247.2023

Abstract

Deteksi mutasi Epidermal Growth Factor Receptor (EGFR) pada pasien kanker paru akan membantu dalam pemilihan targeted therapy yaitu gefitinib. Studi mengenai evaluasi profil keamanan gefitinib di Indonesia sangat terbatas sehingga penelitian ini bertujuan untuk mengetahui efek samping obat hematologi dan non hematologi dari gefitinib pada pasien kanker paru dengan EGFR mutasi positif. Rancangan penelitian adalah observasional cross sectional. Data sekunder diambil melalui rekam medis tahun 2020 sampai 2022 pada 44 pasien. Probabilitas efek samping obat diukur dengan Naranjo Adverse Drug Reaction Probability Scale dan tingkat keparahan efek samping obat dinilai menggunakan Common Terminology Criteria for Adverse Events (CTCAE). Hasil penelitian menunjukkan efek samping hematologi yang paling sering muncul adalah anemia grade 1 pada 18 pasien (40.91%). Pada efek samping non hematologi, rash grade 2 mendominasi pada 20 pasien (45.46%), 14 pasien (31.82%) mengalami peningkatan serum transaminase grade 1, diare grade 1 terjadi pada 5 pasien (11.36%) dan mual muntah grade 2 dialami oleh 3 pasien (6.82%). Total 36 pasien (81.82%) mengalami efek samping dengan 19 kejadian termasuk kategori possible dan 17 kejadian termasuk kategori probable. Efek samping yang muncul bersifat ringan, dapat ditangani dan tidak kumulatif. Tidak didapatkan penyesuaian dosis atau penghentian penggunaan obat yang disebabkan oleh efek samping obat.
Safety profile between fluoxetine and sertraline as antidepressants for pregnant women with depression disorder Dewa Ayu Sri Handani; Mustikawati, Maria Sri Ayu; Parwatininghati, Ni Putu; Zulkarnaen; Akuba, Jusnita
Indonesian Journal of Pharmacology and Therapy Vol 4 No 1 (2023)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.3237

Abstract

Depression disorders are common in women of productive age, especially during pregnancy and peripartum period. Making a decision on the choosing of antidepressants is associated to the biggest concern about the risk of birth defects and major anomalies of their exposure. Decisions of antidepressant use not only involve considering the risks of medications exposure, but also the risks of untreated depression during pregnancy. Evaluation of the safety profile of selective reuptake inhibitors (SSRIs) which are commonly prescribed during pregnancy therefore urgently needed. This review aimed to compare two widely used SSRIs i.e. fluoxentine and sertraline as antidepressants for pregnant women with depression disorder. It is found that sertraline has more positive effects and more safe. Sertraline is well tolerated in pregnant women and breastfeeding mothers with depression disorder.
Co-Authors Akuba, Jusnita Dewa Ayu Sri Handani Fita Rahmawati I Gede Ketut Sajinadiyasa Mustikawati, Maria Sri Ayu Zulkarnaen